Crosslinkable polymer compositions

Abstract

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for controlling the movement of bodily fluid within a patient, among many other uses.

1 . A composition comprising a first polysiloxane having two or more unsaturated groups, a first silanol compound, a first filler, a first hydride material having two or more hydride groups, and a catalyst for catalyzing a reaction between the unsaturated groups and the hydride groups, (a) the composition having a viscosity as measured by oscillatory rheology at 0.1 Hz and 1% strain at 25° C. that is at least ten-fold greater than a viscosity as measured by flow rheology at a frequency of 30 Hz at 25° C., (b) the composition curing when measured at 37° C. within a time period of 1 minute to 120 minutes, (c) after being allowed to anneal for a period of 7 days at 70° C., the composition having a viscosity as measured using oscillatory rheology at a frequency of 0.1 Hz and a strain of 1% at 25° C. or 37° C. is in the range of 3,000 to 40,000 Pa*s, (d) the composition having a combination of properties (a) and (b), (e) the composition having a combination of properties (a) and (c), (f) the composition having a combination of properties (b) and (c), or (g) the composition having a combination of properties (a), (b) and (c). 
     
     
         2 . The composition of  claim 1 , wherein the composition further comprises a first physical crosslinking agent comprising a plurality of hydrogen bonding groups. 
     
     
         3 . The composition of  claim 1 , wherein the composition further comprises a first imaging agent. 
     
     
         4 . The composition of  claim 1 , wherein the unsaturated groups are selected from —CH═CH 2  and —C≡CH groups. 
     
     
         5 . The composition of  claim 1 , wherein the first polysiloxane having two or more unsaturated groups is a vinyl-terminated polysiloxane, an acrylate-terminated polysiloxane, a methacrylate-terminated polysiloxane, or an alkyne-terminated polysiloxane. 
     
     
         6 . The composition of  claim 1 , wherein the first hydride material has between 2 and 20 hydride groups. 
     
     
         7 . The composition of  claim 1 , wherein the catalyst is selected from a platinum catalyst, a rhodium catalyst, a ruthenium catalyst, a palladium catalyst, an iridium catalyst, a boron trihydride catalyst, and a phosphine catalyst. 
     
     
         8 . The composition of  claim 1 , wherein the first silanol compound is a hydroxy-terminated polysiloxane. 
     
     
         9 . The composition of  claim 1 , wherein the first filler is a silica filler characterized by a surface area of 100-500 m 2 /g. 
     
     
         10 . The composition of  claim 1 , wherein the composition contains a catalyst modifier. 
     
     
         11 . A system for controlling the movement of bodily fluid within a patient, comprising: (a) the composition of  claim 1  and (b) a delivery device containing the composition. 
     
     
         12 . The system of  claim 11 , wherein the system comprises two or more composition portions that when combined form the composition and wherein the two or more composition portions comprise a first composition portion and a second composition portion separated from each other within the delivery device. 
     
     
         13 . The system of  claim 12 , wherein the first composition portion comprises the first polysiloxane having two or more unsaturated groups, the first silanol compound, and the first filler; wherein the second composition portion comprises the first hydride material having two or more hydride groups, a second silanol compound, and a second filler;
 wherein the catalyst is within at least one of the first and second composition portions;   wherein the first and second silanol compounds may be the same or different; and   wherein the first and second fillers may be the same or different.   
     
     
         14 . The system of  claim 12 , wherein the first and second composition portions each have a viscosity as measured by oscillatory rheology at 0.1 Hz and 1% strain at 25° C. that is at least ten-fold greater than a viscosity as measured by flow rheology at a frequency of 30 Hz at 25° C. 
     
     
         15 . The system of  claim 13 , (a) wherein the first composition portion further comprises a first physical crosslinking agent comprising a plurality of hydrogen bonding groups and the second composition portion further comprises a second physical crosslinking agent comprising a plurality of hydrogen bonding groups, wherein the first and second physical crosslinking agents may be the same or different and/or (b) wherein the first composition portion further comprises a first imaging agent and the second composition portion further comprises a second imaging agent, wherein the first and second imaging agents may be the same or different. 
     
     
         16 . The system of  claim 12 , wherein the delivery device is configured to mix the first and second composition portions to form the composition in the delivery device and to deliver the composition into a body of the patient. 
     
     
         17 . The system of  claim 16 , wherein the delivery device comprises a first container comprising the first composition portion, a second container comprising the second composition portion, a mixer configured to mix the first and second composition portions, and a catheter.